These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 11704841

  • 1. APL, a model disease for cancer therapies?
    de Thé H, Chelbi-Alix MK.
    Oncogene; 2001 Oct 29; 20(49):7136-9. PubMed ID: 11704841
    [No Abstract] [Full Text] [Related]

  • 2. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
    Strehl S, König M, Boztug H, Cooper BW, Suzukawa K, Zhang SJ, Chen HY, Attarbaschi A, Dworzak MN.
    Leukemia; 2013 Jul 29; 27(7):1606-10. PubMed ID: 23271512
    [No Abstract] [Full Text] [Related]

  • 3. Hot on the TRAIL of acute promyelocytic leukemia.
    Zelent A.
    Nat Med; 2001 Jun 29; 7(6):662-4. PubMed ID: 11385499
    [No Abstract] [Full Text] [Related]

  • 4. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP.
    Proc Natl Acad Sci U S A; 2000 Aug 29; 97(18):10173-8. PubMed ID: 10954752
    [Abstract] [Full Text] [Related]

  • 5. PML nuclear bodies mediate the therapeutic response of APL cells.
    Cancer Discov; 2014 Mar 29; 4(3):OF20. PubMed ID: 24596215
    [Abstract] [Full Text] [Related]

  • 6. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
    Komatsu N.
    Int J Hematol; 2014 Jul 29; 100(1):16-7. PubMed ID: 24912657
    [No Abstract] [Full Text] [Related]

  • 7. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de Thé H.
    Oncogene; 1999 Jan 28; 18(4):1113-8. PubMed ID: 10023688
    [Abstract] [Full Text] [Related]

  • 8. Genetics of APL and the molecular basis of retinoic acid treatment.
    Casini T, Grignani F, Pelicci PG.
    Int J Cancer; 1997 Feb 07; 70(4):473-4. PubMed ID: 9033658
    [No Abstract] [Full Text] [Related]

  • 9. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D, Nasr R, de The H.
    Int J Biochem Cell Biol; 2007 Feb 07; 39(6):1063-70. PubMed ID: 17468032
    [Abstract] [Full Text] [Related]

  • 10. Resistance to arsenic therapy in acute promyelocytic leukemia.
    Zhu HH, Qin YZ, Huang XJ.
    N Engl J Med; 2014 May 08; 370(19):1864-6. PubMed ID: 24806185
    [No Abstract] [Full Text] [Related]

  • 11. Autophagic degradation of an oncoprotein.
    Bøe SO, Simonsen A.
    Autophagy; 2010 Oct 08; 6(7):964-5. PubMed ID: 20724820
    [Abstract] [Full Text] [Related]

  • 12. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F, Hasan SK.
    Best Pract Res Clin Haematol; 2014 Mar 08; 27(1):3-9. PubMed ID: 24907012
    [Abstract] [Full Text] [Related]

  • 13. Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities.
    Rérolle D, Wu HC, de Thé H.
    Cold Spring Harb Perspect Med; 2024 Sep 03; 14(9):. PubMed ID: 38503502
    [Abstract] [Full Text] [Related]

  • 14. Advanced progress on the relationship between RA and its receptors and malignant tumors.
    Li M, Sun Y, Guan X, Shu X, Li C.
    Crit Rev Oncol Hematol; 2014 Sep 03; 91(3):271-82. PubMed ID: 24793539
    [Abstract] [Full Text] [Related]

  • 15. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Tong H, Li K, Mei C, Wang H, Chen Z, Jin J.
    Ann Hematol; 2011 Dec 03; 90(12):1493-4. PubMed ID: 21431323
    [No Abstract] [Full Text] [Related]

  • 16. ATRA(ouble) in the treatment of acute promyelocytic leukemia.
    Ozpolat B, Lopez-Berestein G, Mehta K.
    J Biol Regul Homeost Agents; 2001 Dec 03; 15(2):107-22. PubMed ID: 11501968
    [Abstract] [Full Text] [Related]

  • 17. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Dec 03; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 18. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
    Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H.
    Nat Med; 2001 Jun 03; 7(6):680-6. PubMed ID: 11385504
    [Abstract] [Full Text] [Related]

  • 19. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E.
    Oncogene; 1995 Jun 15; 10(12):2307-14. PubMed ID: 7784078
    [Abstract] [Full Text] [Related]

  • 20. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
    Gu BW, Xiong H, Zhou Y, Chen B, Wang L, Dong S, Yu ZY, Lu LF, Zhong M, Yin HF, Zhu GF, Huang W, Ren SX, Gallagher RE, Waxman S, Chen GQ, Wang ZG, Chen Z, Fu G, Chen SJ.
    Proc Natl Acad Sci U S A; 2002 May 28; 99(11):7640-5. PubMed ID: 12032336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.